Non-alcoholic Fatty Liver Disease

Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Also Known As:

Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Fatty Livers, Nonalcoholic; Liver, Nonalcoholic Fatty; Livers, Nonalcoholic Fatty; Non alcoholic Fatty Liver Disease; Nonalcoholic Fatty Liver; Nonalcoholic Fatty Livers; Nonalcoholic Steatohepatitides; Steatohepatitides, Nonalcoholic; Steatohepatitis, Nonalcoholic

Networked: 21262 relevant articles (2046 outcomes, 4945 trials/studies)

Relationship Network

Disease Context: Research Results

Digestive System Diseases: 1042
- Liver Diseases: 41660
  - Fatty Liver: 12465
    - Non-alcoholic Fatty Liver Disease: 21262

Related Diseases

1.	Non-alcoholic Fatty Liver Disease
2.	Insulin Resistance
3.	Inflammation (Inflammations)
4.	Fibrosis (Cirrhosis)
5.	Obesity

Experts

1.	Nobili, Valerio: 144 articles (01/2020 - 05/2005)
2.	Sanyal, Arun J: 133 articles (12/2022 - 06/2003)
3.	Loomba, Rohit: 132 articles (10/2022 - 08/2007)
4.	Alisi, Anna: 105 articles (05/2022 - 10/2007)
5.	Valenti, Luca: 97 articles (03/2022 - 02/2002)
6.	Nakajima, Atsushi: 96 articles (12/2022 - 10/2006)
7.	Targher, Giovanni: 95 articles (12/2022 - 12/2005)
8.	Younossi, Zobair M: 86 articles (11/2022 - 03/2005)
9.	Yoneda, Masato: 84 articles (12/2022 - 10/2006)
10.	Bugianesi, Elisabetta: 79 articles (12/2022 - 01/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Non-alcoholic Fatty Liver Disease:

1.	LipidsIBA 06/01/2023 - "In this study, we found that the inhibition of hepatocyte PLD1 exerted potent protective effects against HFD-induced NAFLD, which were attributable to a reduction in PPARγ/CD36 pathway-mediated lipid accumulation in hepatocytes. " 07/01/2019 - "Our results also showed that obvious lipid accumulation and inflammatory injury occurred in the liver tissue of HFD-fed mice, while treatment with lentiviral vector short hairpin TREM showed marked improvement in tissue morphology and architecture and less lipid accumulation, thus deciphering the mechanism through which knockdown of TREM-1 ameliorated the inflammatory response and lipid accumulation of NAFLD mice through inactivation of the nuclear factor-κB (NF-κB) and PI3K/AKT signal pathways, respectively. " 10/27/2014 - "There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD. " 12/01/2018 - "In conclusion, our study demonstrates that AAPC significantly ameliorates NAFLD by inhibiting the ERS pathway and lipid deposition, which may be a potential natural medicine for the treatment of NAFLD." 07/01/2023 - "YCHT significantly reduced liver lipid storage and improved the liver pathological status of NAFLD mice. "
2.	Glucose (Dextrose)FDA LinkGeneric 09/01/2022 - "During a median follow-up of 4.3 years, participants with NAFLD had a significantly higher risk of progressing from normal glucose tolerance to diabetes (3.36 [1.60-7.07]) and lower likelihood of diabetes remission (0.48 [0.30-0.78]). " 01/01/2022 - "Hmgcs2 heterozygous adult mice, which exhibited lower ketogenic activity, were more susceptible to diet-induced NAFLD development, whereas HMGCS2 overexpression in NAFLD mice improved hepatosteatosis and glucose homeostasis. " 01/01/2023 - "Conversely, overexpression of GKRP in diabetic rats improved glucose tolerance without causing NAFLD, suggesting the crucial regulatory role of GKRP in maintaining hepatic glucose and lipid metabolism balance. " 01/01/2022 - "Furthermore, the knockdown of the PAF receptor gene in the animal models of NAFLD helped reduce the inflammatory response, improve glucose homeostasis and delay the development of NAFLD. " 01/01/2021 - "A total of 12 weeks of VC supplementation, especially 1,000 mg/day, improved liver health and glucose metabolism in patients with NAFLD. "
3.	EnzymesIBA 01/01/2022 - "All calorie restrictive dietary interventions are beneficial for reducing weight, liver fat content and liver enzymes in individuals with NAFLD. " 01/01/2016 - "LCD consumption in subjects with NAFLD led to a significant reduction in IHLC, but did not significantly affect the concentration of liver enzymes." 01/01/2013 - "After an aerobic exercise, serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease was significant improved in case group (ALT (P= 0.0001), AST (P = 0.01). " 01/01/2021 - "The Efficacy of Plantago major Seed on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial." 01/01/2018 - "The greater efficacy of L-PC seen in NAFLD volunteers may reflect improved bioavailability of PC owing to better protection of the microencapsulated PC from gastrointestinal enzymes and possibly enhanced hepatic delivery of L-PC particles."
4.	Triglycerides (Triacylglycerol)IBA 01/01/2023 - "BFKB8488A was adequately tolerated in patients with T2DM or NAFLD, leading to triglyceride reduction, HDL improvements, and trends in improvement in markers of liver health for both populations and marked liver fat reduction in patients with NAFLD. " 05/01/2014 - "In two NAFLD mouse models, treatment with rCT-1 for 10days induced a marked decrease in liver triglyceride content with augmented proportion of poly-unsaturated FA and reduction of monounsaturated species. " 06/01/2021 - "Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease." 01/01/2018 - "Mice in GP treatment group displayed improved hepatic triglycerides content with lower lipid droplet in hepatocyte and NAFLD activity score. " 09/14/2023 - "This study aimed to investigate the relation between serum triglyceride (TG) and the severity of AP with NAFLD by collecting clinical data from AP patients with NAFLD. "
5.	AntioxidantsIBA 01/01/2021 - "The Nrf2-Keap1 pathway is important for cell antioxidant protection, while its role in exogenous antioxidant mediated protection against NAFLD is unclear. " 01/01/2021 - "Healthy diet and physical activity have been shown to be effective on NAFLD also with antioxidant mechanisms, but compliance to these lifestyles is very low. " 01/01/2021 - "Dietary cocoa ameliorates non-alcoholic fatty liver disease and increases markers of antioxidant response and mitochondrial biogenesis in high fat-fed mice." 06/27/2022 - "The present data show that the reduction of IFC is associated with an improvement in pro/antioxidant and pro-inflammatory status and a better cardiorespiratory fitness in NAFLD patients." 10/07/2003 - "The potential therapeutic efficacy of antioxidants in NAFLD is unknown. "
6.	CholesterolIBA 01/01/2023 - "A significant reduction in expression and function of several hepatic uptake transporters, upregulation of many efflux transporters, downregulation of cholesterol efflux transporters, and mislocalization of canalicular transporter ABCC2 are associated with NAFLD progression. " 01/01/2016 - "Adzuki bean ameliorates hepatic lipogenesis and proinflammatory mediator expression in mice fed a high-cholesterol and high-fat diet to induce nonalcoholic fatty liver disease." 01/30/2024 - "A mice model was established by high fat and high cholesterol diet (HFHCD) to study the benefits of CSBTA on the progression of NAFLD. " 11/21/2023 - "This study aimed to explore the association between serum remnant cholesterol and the risk of NAFLD severity. " 01/01/2023 - "This study aimed to reveal the regulatory mechanisms of cholesterol-lowering (CL) probiotics on NAFLD from aspects involved in BA metabolism in FXR gene knockout (FXR-/-) mice. "
7.	Biomarkers (Surrogate Marker)IBA 01/01/2023 - "However, due to the global epidemic of NAFLD, where invasive liver biopsy is the gold standard for diagnosis, it is necessary to identify a more practical method for early NAFLD diagnosis with useful therapeutic targets; as such, molecular biomarkers could most readily serve these aims. " 04/21/2020 - "Given the increased economic and health burden associated with the NAFLD epidemic, improved methods of population-based, minimally-invasive methods and biomarkers are clearly highly sought and necessary. " 07/01/2018 - "We consider very important for our patients the development of new non-invasive biomarkers for early diagnosis of NAFLD and NASH, as the "gold-standard" of liver biopsy is not easily accepted in clinical practice. " 11/10/2023 - "Clarifying the immune environment of the NAFLD liver to determine its interactions with biomarkers would be beneficial in exploring the mechanisms of disease development. " 05/01/2020 - "Serum measurements and liver ultrasound analyses showed that concomitant administration of BPF and CyC produced significant improvement of NAFLD biomarkers in patients with T2DM. "
8.	Pioglitazone (Actos)FDA Link 01/01/2018 - "Our results showed that NAFLD was improved significantly by pioglitazone in a CAR deletion state. " 11/18/2022 - "Pioglitazone intake is effective in nonalcoholic steatohepatitis management." 04/01/2014 - "Pioglitazone (15 mg/day), which has been identified to be effective for nonalcoholic steatohepatitis, was then administered. " 07/01/2012 - "Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. " 01/01/2019 - "Use of pioglitazone seemed to be protective against the development of NAFLD. "
9.	Fatty Acids (Saturated Fatty Acids)IBA 01/01/2016 - "Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD." 03/01/2014 - "Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]." 10/01/2023 - "These results suggest that WS-S ameliorates NAFLD by regulating fatty acid metabolism via the AMPK pathway." 01/01/2023 - "Moreover, the efficacy of fatty acids for treating NAFLD was full of discrepancies. " 01/01/2022 - "Taken together, these data suggest that spexin ameliorates NAFLD by improving lipolysis and fatty acid oxidation via activation of GALR2 signaling."
10.	Metformin (Glucophage)FDA LinkGeneric 01/01/2015 - "Metformin was the most effective in attenuation of hyperreactivity in all groups of patients with non-alcoholic fatty liver disease, but in obese patients the effectiveness of metformin was weaker than in lean. " 01/01/2013 - "Recent studies have indicated that metformin could improve IR and may be beneficial in the treatment of NAFLD. " 05/01/2010 - "Metformin does not appear to cause or exacerbate liver injury and, indeed, is often beneficial in patients with nonalcoholic fatty liver disease. " 01/01/2018 - "Metformin is now recommended and effective for the treatment of NAFLD. " 01/01/2009 - "Treatment with metformin for 6 months was no better than placebo in terms of improvement in liver histology in patients with NAFLD. "

Therapies and Procedures

1.	Therapeutics 03/16/2023 - "Given the need for patients to play an active role in the behavioral therapy for NAFLD, we advocate that a multidisciplinary approach be adopted, including a psychological support to obtain the best results over time." 09/27/2022 - "This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development." 05/01/2016 - "While simple to recommend, diet and lifestyle measures as a first-line therapy for nonalcoholic steatohepatitis (NASH) are hardly a model of successful therapy, as most clinicians can testify. " 01/01/2020 - "Finally, although no therapies are currently licensed for the treatment of NAFLD, there are interventions that appear to have proven efficacy in randomized controlled trials as well as an extensive emerging therapeutic landscape of new agents that target many of the fundamental pathophysiological processes that drive NAFLD. " 01/01/2021 - "NAFLD-HCC patients undergoing all forms of curative therapy were similarly associated with improved OS (HR 0.96; 95% CI 0.86-1.06; p = 0.40) and DFS (HR 0.85; 95% CI 0.74-0.98; p = 0.03), albeit results being significant only for DFS. "
2.	Bariatric Surgery 01/01/2023 - "Bariatric surgery (BS) is considered to be the most effective treatment for NAFLD. " 12/01/2020 - "For patients with NAFLD, bariatric surgery is the best treatment. " 01/01/2019 - "While bariatric surgery has been shown to improve nonalcoholic fatty liver disease, very few studies have compared liver parameters after both procedures. " 06/01/2022 - "Bariatric surgeries are promising in controlling de novo and recurrent NAFLD with significant reduction in abdominal adipose tissue, despite the optimal timing is inconclusive in LT cases. " 01/01/2023 - "Even bariatric surgery significantly changes the gut microbiota, mostly due to the modification of the gastrointestinal anatomy, with a parallel improvement in histological features of NAFLD. "
3.	Drug Therapy (Chemotherapy) 01/01/2023 - "Since there is currently no specific pharmacotherapy effective for NAFLD, lifestyle modification and prevention of complications are important to improve prognosis. " 01/01/2019 - "There is a marked need for improved animal models of nonalcoholic steatohepatitis (NASH) to facilitate the development of more efficacious drug therapies for the disease. " 01/01/2018 - "No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is lifestyle modifications focusing on bodyweight loss, notoriously difficult to obtain and even more difficult to maintain. " 01/01/2013 - "A better understanding of these relationships is a prerequisite for developing improved drug dosing algorithms for the pharmacotherapy of patients with different stages of NAFLD." 10/01/2012 - "Although pharmacotherapy has been studied in clinical trials, lifestyle modification by diet and exercise remains the mainstay of treatment for NAFLD/NASH."
4.	Gastrectomy 01/01/2020 - "Laparoscopic Sleeve Gastrectomy on the Horizon as a Promising Treatment Modality for NAFLD." 11/30/2021 - "Sleeve gastrectomy and RYGB improved hepatosteatosis and reduced the hepatic ANGPTL8 expression in the preclinical model of NAFLD. " 01/01/2020 - "We studied the relationship between nesfatin-1 changes after laparoscopic sleeve gastrectomy (LSG) and NAFLD remission. " 06/18/2023 - "The study included 55 patients with non-alcoholic fatty liver disease who underwent laparoscopic sleeve gastrectomy at a tertiary institution. " 06/18/2023 - "The aim of this study was to evaluate the effect of laparoscopic sleeve gastrectomy on the resolution of non-alcoholic fatty liver disease. "
5.	Glycemic Control 04/01/2017 - "Glycemic control and NAFLD improved significantly. " 01/01/2023 - "The data of the present study indicate that the APRI score can be used to assess the IR degree and provide important information for improving glycemic control in T2DM patients with NAFLD." 01/01/2021 - "This link could be further characterized in future studies assessing the degree of glycemic control and its relationship with mortality in patients with diabetes and NAFLD." 01/01/2021 - "Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. " 10/06/2023 - "For patients with NAFLD/NASH, DMR has the trend to improve liver fat at 12 weeks, and glycemic control in terms of HbA1c level at 24 weeks based on a very low quality of evidence."